Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the "Arrangement") involving the Company and Exopharm Limited CAN 163 765 991 at the Company's annual general and special meeting of securityholders (the "Meeting") held on March 8, 2024. The Company is also pleased to announce that the Supreme Court of British Columbia issued its Final Order approving the Arrangement on March 11, 2024.
不列顛哥倫比亞省基洛納/ACCESSWIRE/2024年3月12日/Tryp Therapeutics, Inc.（“Tryp” 或 “公司”）（CSE: TRYP）（OTCQB: TRYPF）欣然宣佈，公司的證券持有人在公司的年度股東和特別會議上以壓倒性多數批准了先前宣佈的涉及公司和Exopharm Limited的安排（“安排”）CAN 163 765 991 證券持有人（“會議”）於2024年3月8日舉行。該公司還高興地宣佈，不列顛哥倫比亞省最高法院於2024年3月11日發佈了批准該安排的最終命令。
The special resolution approving the Arrangement (the "Arrangement Resolution") was required to be approved by at least two-thirds (66 2/3%) of the votes cast by: (i) the Company's shareholders and (ii) the Company's shareholders, option holders and the holders of certain warrants, voting as a class.
批准該安排的特別決議（“安排決議”）必須獲得至少三分之二（66 2/ 3%）的選票的批准：（i）公司股東和（ii）公司股東、期權持有人和某些認股權證的持有人集體投票。
A total of 37,738,906 common shares of Tryp were voted at the Meeting, representing approximately 39.14% of the Common Shares entitled to be voted at the Meeting. Approximately 99.92% of the votes cast by Tryp shareholders were in favor of the Arrangement Resolution. All other matters to be determined at the Meeting also passed by similar overwhelming majorities of votes cast.
會議共對Tryp的37,738,906股普通股進行了投票，約佔有權在會議上投票的普通股的39.14％。在Tryp股東的投票中，約有99.92％贊成該安排決議。有待會議決定的所有其他事項也以類似的壓倒性多數票獲得通過。
Closing of the Arrangement remains subject to satisfaction of certain closing conditions, including receipt of final court, stock exchange and regulatory approvals and the satisfaction of certain conditions set forth in the arrangement agreement. Subject to the satisfaction of these closing conditions, the parties currently expect to complete the Arrangement in late March 2024.
本安排的結束仍需滿足某些成交條件，包括獲得最終法院、證券交易所和監管部門的批准，以及滿足安排協議中規定的某些條件。在滿足這些成交條件的前提下，雙方目前預計將在2024年3月下旬完成該安排。
Further details regarding the Arrangement, including the principal closing conditions and the anticipated benefits for shareholders, can be found in the Company's management information circular dated January 26, 2024 in respect of the Meeting (the "Circular"), which can be found under the Company's SEDAR+ profile at .
有關該安排的更多細節，包括主要成交條件和股東的預期收益，可在公司2024年1月26日發佈的有關會議的管理信息通告（“通函”）中找到，該通告可在公司的SEDAR+簡介下找到，網址爲。
About Tryp
關於 Tryp
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%. The Company also recently announced commencement of patient dosing in a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and is preparing to initiate a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety, and patient experience. For more information, please visit .
Tryp Therapeutics是一家臨床階段的生物技術公司，專注於開發專有的新型配方，用於將psilocin與心理療法結合使用，以治療醫療需求未得到滿足的疾病。Tryp的主要項目 TRP-8803 是注入靜脈注入的迷幻藥（迷幻藥的活性代謝物）的專有配方，可緩解口服迷幻藥的許多缺點，包括：顯著縮短迷幻狀態的發作時間，控制迷幻體驗的深度和持續時間，以及將干預的總體持續時間縮短到商業上可行的時間範圍。該公司已在佛羅里達大學完成了一項治療暴飲暴食症的2a期臨床試驗，該試驗表明，暴飲暴食發作平均減少了80％以上。該公司最近還宣佈開始與密歇根大學合作進行一項治療纖維肌痛的2a期臨床試驗的患者給藥，並準備與麻省總醫院合作啓動一項2a期臨床試驗，該試驗旨在治療腸易激綜合徵患者的腹痛和內臟壓痛。每項研究都利用 TRP-8802（合成口服迷幻藥）來證明這些適應症的臨床益處。如果臨床反應呈陽性，則後續研究預計將使用 TRP-8803（注入靜脈注射的psilocin），這有可能進一步改善療效、安全性和患者體驗。欲了解更多信息，請訪問。
Investor & Media Contact
投資者和媒體聯繫人
Peter Molloy
Chief Business Officer
Tryp Therapeutics Inc.
pmolloy@tryptherapeutics.com
彼得·莫洛伊
首席商務官
Tryp Therapeutics Inc
pmolloy@tryptherapeutics.com
Forward-Looking Information
前瞻性信息
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively referred to herein as "forward-looking statements"). The forward-looking statements herein are made as of the date of this press release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved.
本新聞稿包含適用證券立法所指的 “前瞻性信息” 和 “前瞻性陳述”（此處統稱爲 “前瞻性陳述”）。此處的前瞻性陳述僅在本新聞稿發佈之日作出，除非適用法律要求，否則公司不承擔任何義務更新或修改這些陳述以反映新的信息、估計或觀點、未來事件或業績或其他方面。通常，但並非總是如此，前瞻性陳述可以通過使用 “計劃”、“期望”、“預期”、“預算”、“預算”、“預測”、“預測”、“項目”、“打算”、“目標”、“目標”、“預期” 或 “相信” 等詞語或此類詞語和短語的變體（包括負面變體）來識別，或者可以通過陳述來識別其結果是 “可能”、“可以”、“應該”、“將”、“可能” 或 “將” 採取、發生或實現某些行動。
Forward-looking statements in this press release include: stock exchange and other regulatory approvals and the satisfaction of conditions to closing the Arrangement; and anticipated timing of the closing of the Arrangement. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Tryp to control or predict, that may cause Tryp's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including, but not limited to, the Company not obtaining stock exchange approvals; all conditions to completion of the Arrangement not being satisfied or waived and the Arrangement not being completed as anticipated; and the risk factors set out in the Circular dated and other filings available for review on the Company's profile at . Such forward-looking statements represent management's best judgment based on information currently available. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
本新聞稿中的前瞻性陳述包括：證券交易所和其他監管機構的批准以及協議達成條件的滿足情況；以及《安排》的預計完成時間。前瞻性陳述和信息受各種已知和未知的風險和不確定性的影響，其中許多風險和不確定性超出了Tryp的控制或預測能力，這些風險和不確定性可能導致Tryp的實際業績、業績或成就與由此所表達或暗示的重大差異，並且是根據對此類風險、不確定性和其他因素的假設制定的，包括但不限於公司未獲得證券交易所批准；完成前瞻性陳述的所有條件安排不滿意或豁免，該安排未按預期完成；以及在公司簡介上註明的通函和其他可供審查的文件中列出的風險因素 。 此類前瞻性陳述代表了管理層根據當前可用信息做出的最佳判斷。除非適用的證券法要求，否則公司沒有義務在管理層的信念、估計或觀點或其他因素髮生變化時更新這些前瞻性陳述。任何前瞻性陳述都無法保證，未來的實際業績可能會有重大差異。因此，建議讀者不要過分依賴前瞻性陳述或信息。
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所及其監管服務提供商均未審查本新聞稿的充分性或準確性或承擔責任。
SOURCE: Tryp Therapeutics
來源：Tryp Therapeutics
譯文內容由第三人軟體翻譯。